The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus
Global Heart · 2025
DOI: 10.5334/gh.1466 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift Global Heart, 2025. Verfasst von Daniel Piñeiro und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Ramipril, Atorvastatin, Secondary Prevention, Aspirin. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The SECURE trial demonstrated that the cardiovascular (CV)-polypill (acetylsalicylic acid [ASA] + atorvastatin + ramipril) reduces CV mortality by 33% in patients with acute myocardial infarction compared to standard care. The 2023 ACS ESC Guidelines recommend the polypill to improve outcomes and adherence.
Objective
This study aims to establish a global consensus on the optimal use of the CV-polypill in secondary prevention.
Methods
A two-round, modified Delphi method was used, featuring a 30-statement evidence-based questionnaire validated by eight renowned cardiologists. Fifty clinicians from 19 countries in Europe, Latin America, and Asia were invited to join the Delphi panel. Panelists ranked responses using a three-point Likert scale for agreement and importance. Consensus was defined as ≥80% agreement or rating statements ‘very important’ or ‘important’. Statements without consensus after the first round were refined with evidence and feedback in the second round. Remaining disagreements were resolved in a face-to-face meeting. Descriptive statistics were applied.
Results
Response rate was 76% (round 1) and 74% (round 2); 82% were cardiologists, with 74% frequently recommending the CV-polypill. Consensus was achieved on 93.3% of statements. Research showing a 24% relative risk reduction in major adverse CV events over a median of 3 years with the CV-polypill post-acute myocardial infarction, compared to usual care, reached 97.4% agreement for clinical implementation, and a 100% consensus supported polypill use at hospital discharge or first follow-up visits; 81.1% agreed on a prompt initiation after patient stabilization. There was agreement on algorithms for initiating (97.3%), considering patient preferences (97.4%) to the polypill and its cost savings over usual care (89.5%).
Conclusion
The Delphi consensus on real-world use of a CV polypill (ASA, atorvastatin, and ramipril) for secondary prevention post-acute coronary syndrome supports early initiation (within 8 days or at discharge). The findings provide a foundation to inform practice and policy, identifying priorities for further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Buenos Aires, Argentina.
- Hospital Clínico Universitario, Santiago de Compostela, Galicia, Spain.
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
- Instituto de Investigación Sanitaria de Santiago (IDIS) Santiago de Compostela, Galicia, Spain.
- Centro de Reabilitação Cardiovascular, S. Cardiologia, Centro Hospitalar Universitário Lisboa Norte e Faculdade Medicina Universidade de Lisboa (FMUL), CAML, Lisbon, Portugal.
- Instituto de Medicina Preventiva e Instituto de Saúde Ambiental da FMUL, Lisbon, Portugal.
ORCID-Profile: Daniel Piñeiro, José Ramón González-Juanatey, Ana Abreu, Enrique Gómez Alvarez, Carlos Ponte-Negretti, Burkhard Weisser, Alexander Parkhomenko, Francisco Araújo, Alvaro Sosa-Liprandi
Zitieren
APA
Piñeiro, D., González-Juanatey, J. R., Abreu, A., Alvarez, E. G., Ponte-Negretti, C., Weisser, B., Parkhomenko, A., Araújo, F., & Sosa-Liprandi, A. (2025). The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus. Global Heart. https://doi.org/10.5334/gh.1466
Vancouver
Piñeiro D, González-Juanatey JR, Abreu A, Alvarez EG, Ponte-Negretti C, Weisser B, et al. The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus. Global Heart. 2025. doi:10.5334/gh.1466
BibTeX
@article{Pieiro2025,
author = {Piñeiro, Daniel and González-Juanatey, José Ramón and Abreu, Ana and Alvarez, Enrique Gómez and Ponte-Negretti, Carlos and Weisser, Burkhard and Parkhomenko, Alexander and Araújo, Francisco and Sosa-Liprandi, Alvaro},
title = {The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus},
journal = {Global Heart},
year = {2025},
doi = {10.5334/gh.1466}
}
EUVIMED